Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: There is a need for an economic evaluation of the use of closed system (CSTD) in chemotherapy compounding, especially in resource-constrained settings.
Objective: The objective of this study was to assess the cost saving of the management of cancer drug leftovers before and after introduction of CSTD associated with an extension of the beyond-use date (BUD) of cancer vials. A secondary objective was to estimate the level of minimization of drug wastage.
Materials And Methods: This was a prospective, single-center study with two periods of two months each. The cost of drugs saved by using conventional systems (syringe and needle) without a closed system in the first period was compared to the cost of drugs saved by using the CSTD Chemoclave® system in the second period. The drug waste minimization rate compared actual drug waste to potential waste in Period 2.
Results: In Period 1, the amount of drug saved accounted for an average of 10.3% of the amount used in milligrams and the amount of drug wasted accounted for an average of 18.7%. In period 2, these proportions were 15.2% and 6.4% respectively. The CSTD generated an extra cost of 11,962.5 USD compared to the conventional system. The drug saved cost related only to the CSTD and the acquisition cost of the CSTD was a deficit of -7,444.95 USD and the cost saved from the compounding (CSTD and syringes) was a gain of 1,722.01 USD. The waste minimization represented an average of 72.5% ± 24.4% of potential waste.
Conclusion: The use of CSTD to extend the BUD allowed to reduce waste due to microbiological instability without adding an economic profit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10781552211008527 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute toxicity of local anesthetics used for humans and other animals in the larvae of marine crustacean, red-clawed crab Chiromantes haematocheir.
J Vet Med Sci
September 2025
Noto Marine Laboratory, Institute of Nature and Environmental Technology, Kanazawa University.
Local anesthetics such as lidocaine have been used in humans and other animals to perform surgical procedures, therapeutics, and experiments. Lidocaine discarded into the environment through industrial waste, human and animal excretion, and household waste has been detected in the aquatic environment. For example, lidocaine in rivers, lakes, and influent and effluent water has been detected at wastewater treatment plants (7 ng/L-2.
View Article and Find Full Text PDFEco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.
Pharmacoeconomics
September 2025
Department of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.
Background: Immune checkpoint inhibitors (ICIs) are clinically beneficial but associated with high costs that represent a growing challenge for healthcare budgets and may affect affordability, especially in resource-limited settings. Moreover, the healthcare sector is a significant source of greenhouse gas emissions, and medication-related waste-such as that from vial-based therapies-has been identified as a contributing factor. Alternative dosing strategies could reduce the environmental and financial impact of ICI therapy while maintaining clinical safety and efficacy.
View Article and Find Full Text PDFA target responsive benzimidazole-based self-assembled micellar system embedded smart hydrogel: an integrated approach for quantification and removal of phenylbutazone.
J Mater Chem B
September 2025
Department of Chemistry, Indian Institute of Technology Ropar, Rupnagar, Punjab 140001, India.
The unregulated use and improper disposal of active pharmaceutical ingredients (APIs), particularly phenylbutazone (PBZ), are contaminating water resources and posing serious risks to the food chain. PBZ is a nonsteroidal anti-inflammatory drug (NSAID) commonly used for treating pain and fever in animals, and its persistence in the environment due to inadequate waste management has become a cause of concern. To address this, we report the fabrication of benzimidazole-based self-assembled nanomicelles (R2 NMs) for selective detection and removal of PBZ.
View Article and Find Full Text PDFProtocol for a core outcome set for pharmacological treatments in hospitalised patients with acute viral respiratory infections (COSAVRI).
PLoS One
September 2025
Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Dublin, Ireland.
Background: Acute viral respiratory infections (AVRIs) rank among the most common causes of hospitalisation worldwide, imposing significant healthcare burdens and driving the development of pharmacological treatments. However, inconsistent outcome reporting across clinical trials limits evidence synthesis and its translation into clinical practice. A core outcome set (COS) for pharmacological treatments in hospitalised adults with AVRIs is essential to standardise trial outcomes and improve research comparability.
View Article and Find Full Text PDFDevelopment and Characterization of a Sardine Scale-Chitosan Biomaterial: In Vivo Evaluation for Bone Regeneration in a Rat Osteoporosis Model.
J Biomed Mater Res B Appl Biomater
September 2025
Abyss Ingredients, Caudan, France.
The development of functional materials for osteoporosis is essential for effective bone remodeling. In this context, the extraction of biocompatible implantable biomaterials from bio-waste emerges as a valuable strategy, addressing both environmental challenges and promoting human health. The objective of this work was to evaluate the physicochemical properties of the added-value by-product biomaterial (SS-90), extracted from sardine scales (Sardina Pilchardus) and combined with chitosan (SS-90-CH).
View Article and Find Full Text PDF